CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 292 enrolled
Drug / intervention
Amitriptyline +2 moredrug
Likely dose
Amitriptyline 50 mg by mouth at bedtime for 10 weeks (after 2-week titration from 25 mg), or Escitalopram 10 mg by mouth at bedtime for 12 weeksAI-extracted
Key inclusion· 3
  • Normal esophagogastroduodenoscopy (EGD) within the past 5 years without esophagitis, Barrett's esophagus, cancer, erosions, or ulcer disease
  • Confirmed diagnosis of functional dyspepsia
  • May have failed to adequately respond to antisecretory therapy (first-line therapy for FD); adequate response suggests underlying GERD and unsuitability for this trial
Key exclusion· 10
  • Any documented history of endoscopic esophagitis, or predominant heartburn/acid regurgitation, or these symptoms ≥2 times per week in prior year
  • Adequate response to antisecretory therapy per physician interview
  • Any documented peptic ulcer disease
  • Regular use of NSAIDs except low-dose aspirin ≤325 mg/day

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00248651
NCT00248651Phase 3Completed

Antidepressant Therapy for Functional Dyspepsia

Mayo Clinic·interventional·Posted Nov 4, 2005·Updated Jul 25, 2014

In Brief

A Phase 3 clinical trial evaluating Amitriptyline, Escitalopram, and 1 other intervention for Dyspepsia and Other Specified Disorders of Function of Stomach. Completed, enrolled 292 participants across 8 sites in 2 countries.

Detailed Summary

Functional dyspepsia is a common gastrointestinal disorder. Symptoms can include stomach pain or discomfort, bloating, fullness after eating meals, and nausea. These symptoms often interfere with school and work, and weight loss may occur due to dietary restrictions. The hypothesis of this study was that antidepressant therapy is more effective than placebo in relief of the symptoms of functional dyspepsia, adjusting for psychological and psychiatric co-morbidity. The study also examined if antidepressant therapy reduces disability and improves quality of life in functional dyspepsia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada, United States

Timeline

Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 4, 2005
Enrollment StartOct 1, 2006
Primary CompletionJul 1, 2013
TodayJul 2, 2026
Enrollment to primary: 6.8 yearsPosted 20.7 years ago

Interventions

Amitriptylinedrug

25 mg capsule by mouth at bedtime for two weeks, then 50 mg capsule by mouth at bedtime for 10 weeks. The drug will be provided in blister packs.

Escitalopramdrug

10 mg tablets by mouth at bedtime for 12 weeks. The drug will be provided in blister packs.

Placebodrug

Placebo escitalopram and placebo amitriptyline will be manufactured to ensure all tablets and capsules will be indistinguishable, and provided in blister packs.